Current and Future Directions in Pediatric Allergic Rhinitis

Journal of Allergy and Clinical Immunology: In Practice

Volumn 1, Issue 3, 2013, Pages 214-226

  Gentile, Deborah ^a   Bartholow, Ashton ^a   Valovirta, Erkka ^b   Scadding, Glenis ^c   Skoner, David ^a  

^a ALLEGHENY GENERAL HOSPITAL   (United States)

^b Turku Allergy Center   (Finland)

^c ROYAL NATIONAL THROAT NOSE AND EAR HOSPITAL   (United Kingdom)

Author keywords

Allergic rhinitis; Antihistamines; Intranasal corticosteroids; Leukotriene modifiers; Pediatrics; Specific immunotherapy

Indexed keywords

ALLERGEN; ANTIHISTAMINIC AGENT; AZELASTINE; AZELASTINE PLUS FLUTICASONE PROPIONATE; BECLOMETASONE; BIRCH POLLEN EXTRACT; BUDESONIDE; CETIRIZINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CICLESONIDE; CORTICOSTEROID; CROMOGLYCATE DISODIUM; DECONGESTIVE AGENT; DESLORATADINE; FEXOFENADINE; FLUNISOLIDE; FLUTICASONE PROPIONATE; GRASS POLLEN EXTRACT; HISTAMINE H1 RECEPTOR; IMMUNOGLOBULIN E; IMMUNOGLOBULIN E ANTIBODY; INTERLEUKIN 4; INTERLEUKIN 5; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LEVOCETIRIZINE; LORATADINE; MOMETASONE FUROATE; OLOPATADINE; POLLEN EXTRACT; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADENOIDECTOMY; ALLERGIC RHINITIS; ARTICLE; ASTHMA; ATTENTION DEFICIT DISORDER; AVOIDANCE BEHAVIOR; CHILD; COMORBIDITY; CYTOKINE PRODUCTION; ENZYME IMMUNOASSAY; EVENING DOSAGE; HUMAN; IMMUNE RESPONSE; IMMUNOGLOBULIN PRODUCTION; MORBIDITY; PATHOPHYSIOLOGY; PATIENT CARE; PREVALENCE; RADIOALLERGOSORBENT TEST; SECRETORY OTITIS MEDIA; SINUSITIS; SLEEP DISORDERED BREATHING; SUBCUTANEOUS IMMUNOTHERAPY; SUBLINGUAL IMMUNOTHERAPY; SYSTEMATIC REVIEW; TONSILLECTOMY; TYMPANOSTOMY TUBE; UNITED STATES;

ALLERGIC RHINITIS; ANTIHISTAMINES; INTRANASAL CORTICOSTEROIDS; LEUKOTRIENE MODIFIERS; PEDIATRICS; SPECIFIC IMMUNOTHERAPY;

CHILD; COMORBIDITY; DESENSITIZATION, IMMUNOLOGIC; FORECASTING; HUMANS; PREVALENCE; RHINITIS, ALLERGIC, PERENNIAL;

EID: 84877060497     PISSN: 22132198     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaip.2013.03.012     Document Type: Article

References (156)

1. Asthma and Allergy Foundation of America. Allergy facts and figures. Available from:. Accessed November 2012. http://www.aafa.org.
2. Salo P.M., Calatroni A., Gergen P.J., Hoppen J.A., Sever M.L., Jaramillo R., et al. Allergy-related outcomes in relation to serum IgE: results from the National Health and Nutrition Examination Survey 2005-2006. J Allergy Clin Immunol 2011, 127:1226-1235.e7.
3. Bousquet J., Schunemann H.J., Samolinksi M.D., Demoly P., Baena-Cagnani C.E., Bachert C., et al. Allergic Rhinitis and Its Impact on Asthma (ARAI): achievements in 10 years and future needs. J Allergy Clin Immunol 2012, 130:1049-1062.
4. Meltzer E.O., Nathan R., Derebery J., Stang P.E., Campbell U.B., Yeh W.-S., et al. Sleep, quality of life and productivity impact of nasal symptoms in the United States: findings from the Burden of Rhinitis in America survey. Allergy Asthma Proc 2009, 30:244-254.
5. Meltzer E.O., Blaiss M.S., Derebery J., Mahr T.A., Gordo B.R., Sheth K.K., et al. Burden of allergic rhinitis: results from the Pediatric Allergies in America survey. J Allergy Clin Immunol 2009, 124:s43-s70.
6. Meltzer E.O., Gross G.N., Katial R., Storms W.W. Allergic rhinitis substantially impacts patient quality of life: findings from the Nasal Allergy Survey Assessing Limitations. J Fam Pract 2012, 61(2 Suppl):S5-S10.
7. Meltzer E.O., Bukstein D.A. The economic impact of allergic rhinitis and current guidelines for treatment. Ann Allergy Asthma Immunol 2011, 106:S12-S16.
8. Blaiss M.S. Allergic rhinitis: direct and indirect costs. Allergy Asthma Proc 2010, 31:375-380.
9. Civeliek E., Yavuz S.T., Boz A.B., Orhyan F., Yuksel H., Uner A., et al. Epidemiology and burden of rhinitis and rhinoconjunctivitis in 9 to 11 year old children. Am J Rhinol Allergy 2010, 24:364-370.
10. Dykewicz M.S. Management of rhinitis: guidelines, evidence basis and systematic clinical approach for what we do. Immunol Allergy Clin North Am 2011, 31:619-634.
11. Greiner A.N., Hellings P.W., Rotiroti G., Scadding G.K. Allergic rhinitis. Lancet 2011, 378:2112-2122.
12. Skoner D.P., Gentile D.A., Doyle W.J. Effect on growth of long-term treatment with intranasal acetonide aqueous in children with allergic rhinitis. Ann Allergy Asthma Immunol 2008, 101:431-436.
13. Sastre J., Mosges R. Local and systemic safety of intranasal corticosteroids. J Investig Allergol Clin Immunol 2012, 22:1-12.
14. Gentile D., Skoner D.P. Sublingual immunotherapy in patients with allergic rhinoconjunctivitis. Curr Allergy Asthma Rep 2011, 11:131-138.
15. DiBona D., Plaia A., Leto-Brone M.S., LaPiana S., DiLorenzo G. Efficacy of subcutaneous and sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: a meta-analysis-based comparison. J Allergy Clin Immunol 2012, 130:1097-1107.
16. Durham S.R., Emminger W., Kapp A., DeMonchy J.G., Rak S., Scadding G.K., et al. SQ-standardized grass sublingual immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial. J Allergy Clin Immunol 2012, 129:717-725.
17. von Mutius E., Wiland S.K., Fritzsch C., Duhme H., Keil U. Increasing prevalence of hay fever and atopy among children in Leipzig, East Germany. Lancet 1998, 351:862-866.
18. Wright A.L., Holberg C.J., Martinez F.M., Halonen M., Morgan, Taussing L.M. Epidemiology of physician-diagnosed allergic rhinitis in childhood. Pediatrics 1994, 94:895-901.
19. Bloomfield S.F., Stanwell-Smith R., Crevel R.W., Pickup J. Too clean, or not too clean: the hygiene hypothesis and home hygiene. Clin Exper Allergy 2006, 36:402-425.
20. Heederick D., von Mutius E. Does diversity of environmental exposure matter for the occurrence of allergy and asthma?. J Allergy Clin Immunol 2012, 130:44-50.
21. Gentile D.A., Skoner D.P. Effect of respiratory syncytial virus infection during early infancy on the ontogeny of cytokine immune responses. Allergy Asthma Proc 2002, 23:399-405.
22. Gentile D., Howe-Adams J., Trecki J., Patel A., Angelini B., Skoner D. Association between environmental tobacco smoke and diminished dendritic cell interleukin 10 production during infancy. Ann Allergy Asthma Immunol 2004, 92:433-437.
23. Gruzieva O., Beelander T., Enoroth K., Kull I., Melen E., Nordling E., et al. Traffic related air pollution and development of allergic sensitization in children during the first 8 years of life. J Allergy Clin Immunol 2012, 129:240-246.
24. Walton S., Weir C. The interplay between diet and emerging allergy: what can we learn from indigenous Australians?. Int Rev Immunol 2012, 31:184-201.
25. Sears M.R., Burrows B., Flannery E.M., Herbison G.P., Holdaway M.D. Atopy in childhood, I: gender and allergen related risks for the development of hay fever and asthma. Clin Exp Allergy 1993, 23:941-948.
26. Senes A., Nystad W., Bolle R., Lund E. Diverging prevalence trends of atopic disease in Norwegian children. Results from three cross-sectional studies. Allergy 2005, 60:894-899.
27. Corren J., Manning B.E., Thompson S.F., Strom B.L. Rhinitis therapy and the prevention of hospital care for asthma: a case-control study. J Allergy Clin Immunol 2004, 113:415-419.
28. Perry T.T., Corren J., Philip G., Kim E.H., Conover-Walker M.K., Malice M.P., et al. Protective effect of montelukast on lower and upper respiratory tract responses to short-term at allergen exposure. Ann Allergy Asthma Immunol 2004, 93:431-438.
29. Okubo K., Ogino S., Nagakura T., Ishikawa T. Omalizumab is effective and safe in the treatment of Japanese cedar pollen-induced seasonal allergic rhinitis. Allergol Int 2006, 53:379-386.
30. Novembre E., Galli E., Landi F., Caffarelli C., Pifferi M., De Marco E., et al. Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol 2004, 114:851-857.
31. Niggemann B., Jacobson L., Dreborg S., Ferdousi H.A., Halken S., Høst A., et al. Five-year follow-up on the PAT study: specific immunotherapy and long-term prevention of asthma in children. Allergy 2006, 61:855-859.
32. Teele D.W., Klein J.O., Rosner B. Epidemiology of otitis media during the first seven years of life in children in greater Boston: a prospective, cohort study. J Infect Dis 1989, 160:83-94.
33. Tomonaga K., Kurono Y., Mogi G. The role of nasal allergy in otitis media with effusion. A clinical study. Aca Otolaryngol Suppl 1988, 458:41-47.
34. Caffarelli C., Savini E., Giordano S., Gianlupi G., Cavagni G. Atopy in children with otitis media with effusion. Clin Exp Allergy 1998, 28:591-596.
35. Chantzi F.M., Kafetzis D.A., Bairamis T., Avramidou C., Paleologou N., Grimani I., et al. IgE sensitization, respiratory allergy symptoms, and heritability independently increase the risk of otitis media with effusion. Allergy 2006, 61:332-336.
36. Skoner D.P., Doyle W.J., Fireman P. Eustachian tube obstruction after histamine provocation: a double blind dose-response study. J Allergy Clin Immunol 1987, 79:27-31.
37. Skoner D.P., Doyle W.J., Chamovitz A.H., Fireman P. Eustachian tube obstruction after intranasal challenge with house dust mite. Arch Otolayngol Head Neck Surg 1986, 112:840-842.
38. Nguyen L.H., Manoukian J.J., Sobol S.E., Tewfik T.L., Mazer B.D., Schloss M.D., et al. Similar allergic inflammation in the middle ear and upper airway: evidence linking otitis media with effusion to the united airways concept. J Allergy Clin Immunol 2004, 114:1110-1115.
39. Rachelefsky G.S., Goldberg M., Katz R.M., Boris G., Gyepes M.T., Shapiro M.J., et al. Sinus disease in children with respiratory allergy. J Allergy Clin Immunol 1978, 61:310-314.
40. Huang S.W. The risk of sinusitis in children with allergic rhinitis. Allergy Asthma Proc 2000, 21:85-88.
41. Holzmann D., Willik U., Nadal D. Allergic rhinitis as a risk factor for orbital complication of acute rhinosinusitis in children. Am J Rhinol 2001, 15:387-390.
42. Chng S.Y., Goh D.Y., Wang X.S., Tan T.N., Ong N.B. Snoring and atopic disease: a strong association. Pediatr Pulmonol 2004, 38:210-216.
43. Mbata G.C., Chukwuka J.C. Obstructive sleep apnea hypopnea syndrome. Ann Med Health Sci Res 2012, 2:74-77.
44. McColley S.A., Carroll J.L., Curtis S., Loughlin G.M., Sampson H.A. High prevalence of allergic sensitization in children with habitual snoring and obstructive sleep apnea. Chest 1997, 111:170-173.
45. Juniper E.F., Guyatt G.H., Dolovich J. Assessment of quality of life in adolescents with allergic rhinoconjunctivitis: development and testing of a questionnaire for clinical trials. J Allergy Clin Immunol 1994, 93:413-423.
46. Vuurman E.F., van Veggel L.M., Uiterwijk M.M., Leutner D., O'Hanlon J.F. Seasonal allergic rhinitis and AH effects on children's learning. Ann Allergy 1993, 71:121-126.
47. Borres M.P., Brakenhielm G., Irander K. How many teenagers think they have allergic rhinitis and what they do about it. Ann Allergy Asthma Immunol 1997, 78:29-34.
48. Brawley A., Siverman B., Kearney S., et al. Allergic rhinitis in children with attention-deficit/hyperactivity disorder. Ann Allergy Asthma Immunol 2004, 92:663-667.
49. Bousquet J., Khaltaev N., Cruz A.A., Denburg J., Fokkens W.J., Togias A., et al. Allergic Rhinitis and Its impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN adn AllerGen). Allergy 2008, 63(Suppl 86):8-160.
50. Burbach G.J., Heinzerling L.M., Edenharter G., Bachert C., Bindsley-Jensen C., Bonini S., et al. GA(2)LEN skin test study II: clinical relevance of inhalant allergen sensitizations in Europe. Allergy 2009, 64:1507-1515.
51. Fuiano N., Fusilli S., Incorvaia C. A role for measurement of nasal IgE antibodies in diagnosis of Alternaria-induced rhinitis in children. Allergol Immunopathol (Madr) 2012, 40:71-74.
52. Bachert C. The role of histamine in allergic disease: re-appraisal of its inflammatory potential. Allergy 2002, 57:287-296.
53. Corcostegui R., Labeaga L., Innerarity A., Berisa A., Orjales A. Preclinical pharmacology of bilastine, a new selective histaminen H1-receptor antagonist: receptor selectivity and in vitro AH activity. Drugs R D 2005, 6:371-384.
54. Broide D.H. Allergic rhinitis: pathophysiology. Allergy Asthma Proc 2010, 31:370-374.
55. Osguthorpe J.D. Pathophysiology of and potential new therapies for allergic rhinitis. Int Forum Allergy Rhinol 2012 Nov 28, [Epub ahead of print].
56. Eggleston P.A. Methods and effectiveness of indoor environmental control. Ann Allergy Asthma Immunol 2001, 87:44-47.
57. Boyle R.J., Pedroletti C., Wickman M., Bjermer L., Valovirta E., Dahl R., et al. Nocturnal temperature controlled laminar airflow for treating atopic asthma: a randomised controlled trial. Thorax 2012, 67:215-221.
58. Li H., Sha Q., Zuo K., Jiang H., Cheng L., Shi J., Xu G. Nasal saline irrigation facilitates control of allergic rhinitis by topical steroid in children. J Otorhinolaryngol Relat Spec 2009, 71:50-55.
59. Scadding G.K., Durham S.R., Mirakian R., Jones N.S., Leech S.C., Farooque S., et al. BSACI guidelines for the management of allergic and non-allergic rhinitis. Clin Exp Allergy 2008, 38:19-42.
60. Bousquet J., Lund V.J., Van Cauwenberge P., Bremard-Oury C., Mounedji N., Stevens M.T., et al. Implementation of guidelines for seasonal allergic rhinitis: a randomized controlled trial. Allergy 2003, 58:733-741.
61. Bousquet J., Bodez T., Gehano P., Klossek J.M., Liard F., Neukirch F., et al. Implementation of guidelines for allergic rhinitis in specialist practices. A randomized pragmatic controlled trial. Int Arch Allergy Immunol 2009, 150:75-82.
62. Hampel F., Ratner P., Haeusler J.M. Safety and tolerability of levocetirizine dihydrochloride in infants and children with allergic rhinitis or chronic urticaria. Allergy Asthma Proc 2010, 31:290-295.
63. Shah S., Nayak A., Ratner P., Roland P., Michael W. Effects of olopatadine hydrochloride nasal spray 06% in the treatment of seasonal allergic rhinitis: a phase III, multicenter, randomized, double-blind, active- and placebo-controlled study in adolescents and adults. Clin Ther 2009, 31:99-107.
64. Bachert C., Kuna P., Sanquer F., Ivan P., Dimitrov V., Gorina M.M., et al. Comparison of the efficacy and safety of bilastine 20 mg vs desloratadine 5 mg in seasonal allergic rhinitis patients. Allergy 2009, 64:158-165.
65. Meltzer E.O., Scheinmann P., Rosado Pinto J.E., Bachert C., Hedlin G., et al. Safety and efficacy of oral fexofenadine in children with seasonal allergic rhinitis-a pooled analysis of three studies. Pediatr Allergy Immunol 2004, 15:253-260.
66. Simons F.E., Simons K.J. Histamine and H1-antihistamines: celebrating a century of progress. J Allergy Clin Immunol 2011, 128:1139-1150.e4.
67. Ng K.H., Chong D., Wong C.K., Ong H.T., Lee C.Y., Lee B.W., et al. Central nervous system side effects of first- and second-generation antihistamines in school children with perennial allergic rhinitis: a randomized, double-blind, placebo-controlled comparative study. Pediatrics 2004, 113:e116-e121.
68. Church M.K., Maurer M., Simons F.E.R., Bindslev-Jensen C., Van Cauwenberge P., Bousquet J., et al. Risk of first-generation H(1)-antihistamines: a GA(2)LEN position paper. Allergy 2010, 65:459-466.
69. Weiner J.M., Abramson M.J., Puy R.M. Intranasal corticosteroids versus oral H1 receptor antagonists in allergic rhinitis: systematic review of randomised controlled trials. BMJ 1998, 317:1624-1629.
70. Yáñez A., Rodrigo G.J. Intranasal corticosteroids versus topical H1 receptor antagonists for the treatment of allergic rhinitis: a systematic review with meta-analysis. Ann Allergy Asthma Immunol 2002, 89:479-484.
71. Wilson A.M., O'Byrne P.M., Parameswaran K. Leukotriene receptor antagonists for allergic rhinitis: a systematic review and meta-analysis. Am J Med 2004, 116:338-344.
72. Wilson A.M., Orr L.C., Sims E.J., Lipworth B.J. Effects of monotherapy with intra-nasal corticosteroid or combined oral histamine and leukotriene receptor antagonists in seasonal allergic rhinitis. Clin Exp Allergy 2001, 31:61-68.
73. Anolik R., Pearlman D., Teper A., Gates D. Mometasone furoate improves nasal and ocular symptoms of seasonal allergic rhinitis in adolescents. Allergy Asthma Proc 2009, 30:406-412.
74. Ratner P., Meltzer E., Teper A. Mometasone furoate nasal spray is safe and effective for 1-year treatment of children with perennial allergic rhinitis. Int J Pediatr Otorhinolaryngol 2009, 73:651-657.
75. Wandalsen G., Mendes A., Solq D. Objective improvement in nasal congestion and nasal hyperreactivity with use of nasal steroids in persistent allergic rhinitis. Am J Rhinol Allergy 2010, 24:e32-e36.
76. Nathan R., Berger W., Yang W., Cheema A., Silvey M., Wu W., et al. Effect of once-daily fluticasone furoate nasal spray on nasal symptoms in adults and adolescents with perennial allergic rhinitis. Ann Allergy Asthma Immunol 2008, 100:497-505.
77. Jacobs R., Martin B., Hampel F., Toler W., Ellsworth A., Philpot E. Effectiveness of fluticasone furoate 110 mcg once daily in the treatment of nasal and ocular symptoms of seasonal allergic rhinitis in adults and adolescents sensitized to mountain cedar pollen. Curr Med Res Opin 2009, 25:1393-1401.
78. Vasar M., Houle P., Douglass J., Meltzer E., Silvey M., Wu W., et al. Fluticasone furoate nasal spray: effective monotherapy for symptoms of perennial allergic rhinitis in adults/adolescents. Allergy Asthma Proc 2008, 29:313-321.
79. Fokkens W.J., Jogi R., Reinartz S., Sidorenko I., Sitkauskiene B., van Oene C., et al. Once daily fluticasone furoate nasal spray is effective in seasonal allergic rhinitis caused by grass pollen. Allergy 2007, 62:1078-1084.
80. Ratner P., Wingertzahn M., van Bavel J.H., Hampel F., Darken P., Shah T. Efficacy and safety of ciclesonide nasal spray for the treatment of seasonal allergic rhinitis. J Allergy Clin Immunol 2006, 118:1142-1148.
81. Meltzer E., Kunjibettu S., Hall N., Wingertzahn M., Murcia C., Berger W., et al. Efficacy and safety of ciclesonide, 200 microg once daily, for the treatment of perennial allergic rhinitis. Ann Allergy Asthma Immunol 2007, 98:175-181.
82. Berger W., Nayak A., Lanier B., Kaiser H., LaForce C., Darken P., et al. Efficacy and safety of once-daily ciclesonide nasal spray in children with allergic rhinitis. Pediatr Asthma Allergy Immunol 2008, 21:73-82.
83. Baena C., Patel P. Efficacy and long-term safety of mometasone furoate nasal spray in children with perennial allergic rhinitis. Curr Med Res Opin 2010, 26:2047-2055.
84. Al Sayyad J.J., Fedorowicz Z., Alhashimi D., Jamal A. Topical nasal steroids for intermittent and persistent allergic rhinitis in children. Cochrane Database Syst Rev 2007, (1):CD003163.
85. Meltzer E., Tripathy I., Maspero J., Wu W., Philpot E. Safety and tolerability of fluticasone furoate nasal spray once daily in paediatric patients aged 6-11 years with allergic rhinitis: subanalysis of three randomized, double-blind, placebo-controlled, multicenter studies. Clin Drug Invest 2009, 29:79-86.
86. Bielory L. Ocular symptom reduction in patients with seasonal allergic rhinitis treated with the intranasal corticosteroid mometasone furoate. Ann Allergy Asthma Immunol 2008, 100:272-279.
87. Keith P., Scadding G. Are intranasal corticosteroids all equally consistent in managing ocular symptoms of seasonal allergic rhinitis?. Curr Med Res Opin 2009, 2:2021-2041.
88. Camargos P., Ibiapina C., Lasmar L., Cruz A.A. Obtaining concomitant control of allergic rhinitis and asthma with a nasally inhaled corticosteroid. Allergy 2007, 62:310-316.
89. Pedersen W., Hjuler I., Bisgaard H., Mygind N. Nasal inhalation of budesonide from a spacer in children with perennial rhinitis and asthma. Allergy 1998, 53:383-387.
90. Adams R.J., Fuhlbrigge A.L., Finkelstein J.A., Weiss S.T. Intranasal steroids and the risk of emergency department visits for asthma. J Allergy Clin Immunol 2002, 109:636-642.
91. Crystal-Peters J., Neslusan C., Crown W.H., Torres A. Treating allergic rhinitis in patients with comorbid asthma: the risk of asthma-related hospitalizations and emergency department visits. J Allergy Clin Immunol 2002, 109:57-62.
92. Stelmach R., do Patrocinio T Nunes M., Ribeiro M., Cukier A. Effect of treating allergic rhinitis with corticosteroids in patients with mild-to-moderate persistent asthma. Chest 2005, 128:3140-3147.
93. Allen D.B., Meltzer E.O., Lemanske R.F., Philpot E.E., Faris M.A., Kral K.M., et al. No growth suppression in children treated with the maximum recommended dose of fluticasone propionate aqueous nasal spray for one year. Allergy Asthma Proc 2002, 23:407-413.
94. Schenkel E.J., Skoner D.P., Bronsky E.A., Miller S.D., Pearlman D.S., Rooklin A., et al. Absence of growth retardation in children with perennial allergic rhinitis after one year of treatment with mometasone furoate aqueous nasal spray. Pediatrics 2000, 105:E22.
95. Skoner D.P., Rachelefsky G.S., Meltzer E.O., Chervinsky P., Morris R.M., Seltzer J.M., et al. Detection of growth suppression in children during treatment with intranasal beclomethasone dipropionate. Pediatrics 2000, 105:E23.
96. Mygind N., Laursen L.C., Dahl M. Systemic corticosteroid treatment for seasonal allergic rhinitis: a common but poorly documented therapy. Allergy 2000, 55:11-15.
97. Nasser S.M., Ewan P.W. Lesson of the week: depot corticosteroid treatment for hay fever causing avascular necrosis of both hips. BMJ 2001, 322:1589-1591.
98. Li Albert M., Abdullah V., Tsen C., Au C., Lam H., So H., et al. Leukotriene receptor antagonist in the treatment of childhood allergic rhinitis: a randomized placebo-controlled study. Pediatr Pulmonol 2009, 44:1085-1092.
99. Razi C., Bakirtas A., Harmanci K., Turktas I., Erbas D. Effect of montelukast on symptoms and exhaled nitric oxide levels in 7- to 14-year-old children with seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2006, 97:767-774.
100. Grainger J., Drake-Lee A. Montelukast in allergic rhinitis: a systematic review and meta-analysis. Clin Otolaryngol 2006, 31:360-367.
101. Scadding G.K. Rhinitis medicamentosa. Clin Exp Allergy 1995, 25:391-394.
102. Bousquet J., van Cauwenberge P., Ait Khaled N., Bachert C., Baena-Cagnani C.E., Bouchard J., et al. Pharmacologic and anti-IgE treatment of allergic rhinitis. ARIA update. Allergy 2006, 61:1086-1096.
103. Calderon M.A., Gerth van Wijk R., Eichler I., Matricardi P.M., Varga E.M., Kopp M.V., et al. Perspectives on allergen-specific immunotherapy in childhood: an EAACI position statement. Pediatr Allergy Immunol 2012, 23:300-306.
104. Walker S.M., Durham S.R., Till S.J., Roberts G., Corrigan C.J., Leech S.C., et al. Immunotherapy for allergic rhinitis. Clin Exp Allergy 2011, 41:1177-1200.
105. Kopp M.V. Role of immunmodulators in allergen-specific immunotherapy. Allergy 2011, 66:792-797.
106. Calderon M.A., Alves B., Jacobson M., Hurwitz B., Sheikh A., Durham S. Allergen injection immunotherapy for season allergic rhinitis. Cochrane Database Syst Rev 2007, (1):CD01936.
107. Jacobsen L., Niggemann B., Dreborg S., Ferdousi H.A., Halken S., Høst A., et al. Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow up on the PAT study. Allergy 2007, 62:943-948.
108. Hankin C., Cox L., Lang D., Bronstone A., Fass P., Leatherman B., Wang Z. Allergen immunotherapy and health care cost benefits for children with allergic rhinitis: a large-scale, retrospective, matched cohort study. Ann Allergy Asthma Immunol 2010, 104:79-85.
109. Canonica G.W., Bousquet J., Casale T., Lockey R.F., Baena-Cagnani C.E., Pawankar R., et al. Sub-lingual immunotherapy: World Allergy Organization Position Paper 2009. Allergy 2009, 64(Suppl 91):1-59.
110. Larenas-Linnemann D. Sublingual immunotherapy in children: complete and updated review supporting evidence of effect. Curr Opin Allergy Clin Immunol 2009, 9:168-176.
111. Radulovic S., Wilson D., Calderon M., Durham S. Systematic reviews of sublingual immunotherapy (SLIT). Allergy 2011, 66:740-752.
112. Scadding G.W., Shamji M.H., Jacobson M.R., Lee D.I., Wilson D., Lima M.T., et al. Sublingual grass pollen immunotherapy is associated with increases in sublingual Foxp3-expressing cells and elevated allergen-specific immunoglobulin G4, immunoglobulin A and serum inhibitory activity for immunoglobulin E-facilitated allergen binding to B cells. Clin Exp Allergy 2010, 40:598-606.
113. Krouse J.H. Sublingual immunotherapy for inhalant allergy: cautious optimism. Otolaryngol Head Neck Surg 2009, 140:622-624.
114. Fokkens W.J., Lund V.J., Mullol J., et al. European position paper on rhinosinusitis and nasal polyps 2012. Rhinology 2012, 23:1-298.
115. Canonica G.W., Compalati E. Minimal persistent inflammation in allergic rhinitis: implications for current treatment strategies. Clin Exp Immunol 2009, 158:260-271.
116. Shreffler W.G. Microarrayed recombinant allergens for diagnostic testing. J Allergy Clin Immunol 2011, 127:843-849.
117. Valenta R., Lidholm J., Niederberger V., Hayek B., Kraft D., Grönlund H. The recombinant allergen-based concept of component-resolved diagnostics and immunotherapy (CRD and CRIT). Clin Exp Allergy 1999, 29:896-904.
118. Sastre J. Molecular diagnosis in allergy. Clin Exp Allergy 2010, 40:1442-1460.
119. Nicolaou N., Poorafshar M., Murray C., Simpson A., Winell H., Kerry G., et al. Allergy or tolerance in children sensitized to peanut: prevalence and differentiation using component-resolved diagnostics. J Allergy Clin Immunol 2010, 125:191-197. e1-13.
120. Jahn-Schmid B., Harwanegg C., Hiller R., Bohle B., Ebner C., Scheiner O., et al. Allergen microarray: comparison of microarray using recombinant allergens with conventional diagnostic methods to detect allergen-specific serum immunoglobulin E. Clin Exp Allergy 2003, 33:1443-1449.
121. Wohrl S., Vigl K., Zehetmayer S., Hiller R., Jarisch R., Prinz M., et al. The performance of a component-based allergen-microarray in clinical practice. Allergy 2006, 61:633-639.
122. Wallace D.V., Dykewicz M.S., Bernstein D.I., Blessing-Moore J., Cox L., Khan D.A., et al. The diagnosis and management of rhinitis: an updated practice parameter. J Allergy Clin Immunol 2008, 122:S1-84.
123. Brozek J.L., Bousquet J., Baena-Cagnani C.E., Bonini S., Canonica G.W., Casale T.B., et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol 2010, 126:466-476.
124. Muraro A., Clark A., Beyer K., Borrego L.M., Borres M., Lodrup Carlsen K.C., et al. The management of the allergic child at school. Allergy 2010, 65:681-689.
125. Gibson TB, Fendrick AM, Chernew ME. Cost-sharing and productivity. Working Paper 18402. Available from:. Accessed November 15, 2012. http://www.nber.org/papers/w18402.
126. Montreal Protocol. Available from:. Accessed March 13, 2012. http://www.epa.gov/ozone/intpol/.
127. Meltzer E.O., Jacobs R., LaForce C., Kelley C.L., Dunbar S.A., et al. Safety and efficacy of once-daily treatment with beclomethasone dipropionate nasal aerosol in subjects with perennial allergic rhinitis. Allergy Asthma Proc 2012, 33:249-257.
128. Ratner P., Jacobs R., Mohar D., Huang H., Desai S.Y., Hinkle J. Evaluation of the efficacy and safety of ciclesonide hydrofluoroalkane nasal aerosol, 80 or 160 μg once daily, for the treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2010, 105:471-479.
129. Luskin A.T. Is there a role for aerosol nasal sprays in the treatment of allergic rhinitis. Allergy Asthma Proc 2011, 32:168-177.
130. Kaiser H.B., Naclerio R.M., Given J., Toler T.N., Ellsworth A., Philpot E.E. Fluticasone furoate nasal spray: a single treatment option for the symptoms of seasonal allergic rhinitis. J Allergy Clin Immunol 2007, 119:1430-1437.
131. Fluticasone furoate: a randomized, double-blind, placebo-controlled, parallel-group, multi-center study to evaluate the effects of a one-year course of fluticasone furoate nasal spray 110 μg QD on growth in pre-pubescent, pediatric patients with perennial allergic rhinitis. Available from:. Accessed February 21, 2013. http://clinicaltrials.gov/ct2/show/results/NCT00570492?term=allergic%2Brhinitis&intr=fluticasone&rank=24§=X36015.
132. Lee T., Pickard S. Meta-analysis of azelastine nasal spray for the treatment of allergic rhinitis. Pharmacotherapy 2007, 27:852-859.
133. Chipps B., Spector S., Farrar J., Carr W., Meltzer E., Storms W., et al. Differences in recommendations between the Allergic Rhinitis and its Impact on Asthma Update 2010 and US Rhinitis Practice Parameters. J Allergy Clin Immunol 2011, 127:1640-1641.
134. Ratner P.H., van Bavel J.H., Martin B.G., Hampel F.C., Howland W.C., Rogenes P.R., et al. A comparison of the efficacy of fluticasone propionate aqueous nasal spray and loratadine, alone and in combination, for the treatment of seasonal allergic rhinitis. J Fam Pract 1998, 47:118-125.
135. Juniper E.F., Kline P.A., Hargreave F.E., Dolovich J. Comparison of beclomethasone dipropionate aqueous nasal spray, astemizole, and the combination in the prophylactic treatment of ragweed pollen-induced rhinoconjunctivitis. J Allergy Clin Immunol 1989, 83:627-633.
136. Barnes M.L., Ward J.H., Fardon T.C., Lipworth B.J. Effects of levocetirizine as add-on therapy to fluticasone in seasonal allergic rhinitis. Clin Exp Allergy 2006, 36:676-684.
137. Di Lorenzo G., Pacor M.L., Pellitteri M.E., Morici G., Di Gregoli A., Lo Bianco C., et al. Randomized placebo-controlled trial comparing fluticasone aqueous nasal spray in mono-therapy, fluticasone plus cetirizine, fluticasone plus montelukast and cetirizine plus montelukast for seasonal allergic rhinitis. Clin Exp Allergy 2004, 34:259-267. [published correction appears in Clin Exp Allergy 2004;34:1329].
138. Carr W., Bernstein J., Lieberman P., Meltzer E.O., Bachert C., Price D., et al. A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis. J Allergy Clin Immunol 2012, 129:4252-4259.
139. Hampel F.C., Ratner P.H., Van Bavel J., Amar N.J., Deftary P., Wheeler W., et al. Double-blind, placebo-controlled study of azelastine and fluticasone in a single nasal spray delivery device. Ann Allergy Asthma Immunol 2010, 105:168-173.
140. Ratner P.H., Hampel F., Van Bavel J., Amar N.J., Daftary P., Wheeler W., et al. Combination therapy with azelastine hydrochloride nasal spray and fluticasone propionate nasal spray in the treatment of patients with seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2008, 100:74-81.
141. Blaiss M., Maloney J., Nolte H., Gawchik S., Yao R., Skoner D.P. Efficacy and safety of timothy grass allergy immunotherapy tablets in North American children and adolescents. J Allergy Clin Immunol 2011, 127:64-71.
142. Nelson H.S., Nolte H., Creticos P., Maloney J., Wu J., Bernstein D.I. Efficacy and safety of timothy grass allergy immunotherapy tablet treatment in North American adults. J Allergy Clin Immunol 2011, 127:72-80. 80.e1-2.
143. Skoner D., Gentile D., Bush R., Fasano M.B., McLaughlin A., Esch R.E. Sublingual immunotherapy in patients with allergic rhinoconjunctivitis caused by ragweed pollen. J Allergy Clin Immunol 2010, 125:660-666.
144. Durham S.R., Yang W.H., Pedersen M.R., Johansen N., Rak S. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006, 117:802-809.
145. Durham S.R., Emminger W., Kapp A., Colombo G., de Monchy J.G., Rak S., et al. Long-term clinical efficacy in grass pollen-induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet. J Allergy Clin Immunol 2010, 125:131-138.e1-7.
146. Bousquet J., Annesi-Maesano I., Carat F., Leger D., Rugina M., Pribil C., et al. Characteristics of intermittent and persistent allergic rhinitis: DREAMS study group. Clin Exp Allergy 2005, 35:728-732.
147. Arbes S.J., Gergen P.J., Elliott L., Zeldin D.C. Prevalences of positive skin test responses to 10 common allergens in the US population: results from the third National Health and Nutrition Examination Survey. J Allergy Clin Immunol 2005, 116:377-383.
148. Qin S., Cobbold S.P., Pope H., Elliott J., Kioussis D., Davies J., Waldmann H. "Infectious" transplantation tolerance. Science 1993, 259:974-977.
149. O'Hehir R.E., de Leon M.P., Hales B.J., Biondo M., Douglass J.A., Rolland J.M., et al. House dust mite sublingual immunotherapy: the role for transforming growth factor-beta and functional regulatory T cells. Am J Respir Crit Care Med 2009, 180:936-947.
150. Roschmann K.L., van Kuijen A.M., Luiten S., Jonker M.J., Breit T.M., Fokkens W.J., et al. Purified Timothy grass pollen major allergen Phl p 1 may contribute to the modulation of allergic responses through a pleotropic induction of cytokines and chemokines from airway epithelial cells. Clin Exp Immunol 2012, 167:413-421.
151. Brass E.P. Changing the status of drugs from prescription to over-the-counter availability. N Engl J Med 2001, 345:810-816.
152. Bielory L., Blaiss M., Fineman S.M., Ledford D.K., Lieberman P., Simons F.E., et al. Concerns about intranasal corticosteroids for over-the-counter use: position statement of the Joint Task Force for the American Academy of Allergy, Asthma and Immunology and the American College of Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol 2006, 96:514-525.
153. Food and Drug Administration. Orally inhaled and intranasal corticosteroids: evaluation of the effects on growth in children. 2007. Available from:. Accessed April 14, 2010. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071968.pdf.
154. Kelly H.W., Sternberg A.L., Lescher R., Ruhlbrigge A.L., Williams P., Zeiger R.S., et al. Effect of inhaled glucocorticoids in childhood on adult height. N Engl J Med 2012, 367:904-912.
155. Philip G., Hustad C., Noonan G., Malice M.P., Ezekowitz A., Reiss T.F., et al. Reports of suicidality in clinical trials of montelukast. J Allergy Clin Immunol 2009, 124:691-696.
156. Duke J., Friedlin J., Li X. Consistency in the safety labeling of bioequivalent medications. Pharmacoepidemiol Drug Saf 2013, 22:294-301.